TLS at DIA 2013
TLS had the priveldge to speak on two panels at this week's Drug Information Association anuual meeting in Boston. I'm sure that some TLS members were in attendence. On Tuesday I spoke on the Reinventing the R&D Business Model: Heeding the President’s PCAST Report on Innovation panel, hosted by the Tufts Center for the Study of Drug Development. The discussion was of course informative, but I think it's also important to take a moment to realize the transition that has brought us to this point. When I first began casually speaking about the TLS model, the terms openness and transparency were not being spoken, let alone being en vogue. It's so gratifying to watch the forum for these ideas grow throughout the industry.
After I spoke on Tuesday, our COO Marc Foster spoke on the Clinical Trial Visit of the Future: Leveraging Emerging Technologies to Crack the Patient Recruitment Challenge. Here Marc was able to examine the increasing number of remote data collection possibilities in the field. As you may know, our lisinopril study uses mostly remote monitoring, so it was great to see a panel reinforce a major tenet of our model.
We have more speaking slots booked for later in the summer, so stay tuned for more updates.